linjc16/ctgov huggingface dataset:
Fentanyl Test in Children's Adenotonsillectomy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to discuss the relationship between the result of fentanyl test and required dosage of morphine for children with OSAS after adenotonsillectomy；and to evaluate the ability of predicting requested dosage of morphine postoperatively.

Detailed Description
-----------------
All the patients were intubated. Sevoflurane was used for maintenance without any opioids. Before the end of the procedure, spontaneous respiratory was recovered. All the patients were given 1 mcg/kg fentanyl i.v. after the end of the procedure. The positive result was defined as spontaneous respiratory rate decreased more than 50%, the others were defined as negative result. All the patients were given morphine for pain relief according to our protocol after extubation.

Official Title
-----------------
Fentanyl Test Results and Its Association With Morphine Requirements in Children With Obstructive Sleep Apnea Syndrome After Adenotonsillectomy

Conditions
-----------------
Obstructive Sleep Apnea

Intervention / Treatment
-----------------
* Drug: Fentanyl


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:meet all of the following the American society of anesthesiologists (ASA) class Ⅰ   Ⅱ the age of 3   7 years old children who underwent selective adenotonsillectomy. Exclusion Criteria:meet anyone of the following craniofacial malformations mental retardation BMI > 22 kg/m2 a history of bronchial asthma a recent history of opioid use.

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Fentanyl|Before the end of the procedure, spontaneous respiratory was recovered. All the patients were given 1 mcg/kg fentanyl i.v. after the end of the procedure.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rescue Morphine Requirement |  | average 1 hour from extubation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-operative Nausea and Vomiting |  | average 1 hour from extubation | 
| Number of Participants With Pulse Oxygen Saturation Less Than 95 Percent |  | average 1 hour from extubation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adenotonsillectomy, fentanyl
Drug Interactions and Hip Fracture Risk in Older Adults

Study Overview
=================
Brief Summary
-----------------
Older people are in great risk of hip fracture for multiple reasons. Also they often are on medications for medical conditions. Hip fracture risk increases in relation to some medications. When older peoples take 2 or more medications they are in increase risk of hip fracture.

Detailed Description
-----------------
In this study the investigators describe medication intake profile and identify older people risk of hip fracture in relation to their medication when they are taken together.

Official Title
-----------------
Drug Interactions and Hip Fracture Risk in Older Adults

Conditions
-----------------
Hip Fractures

Intervention / Treatment
-----------------
* Drug: drug interaction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: * Affiliated patients to the HMO Plan de Salud Hospital Italiano at least 6 months affiliated. older than 64 years old * affiliated between 01/07/2014 al 31/12/2019. Exclusion Criteria: Pathological Hip fracture bilateral elective hip replacement previous study period

Ages Eligible for Study
-----------------
Minimum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cases with hip fracture<br>Patients afiliated to a HMO Plan de Salud Hospital Italiano who presented hip fracture between 2014 and 2019 | Drug: drug interaction<br>* when two drugs are taken together<br>|
| controls without hip fracture<br>Patients afiliated to a HMO Plan de Salud Hospital Italiano without hip fracture between 2014 and 2019 | Drug: drug interaction<br>* when two drugs are taken together<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hip fracture | non pathological hip fracture | 1 year |
Evaluation of the Measurement of Cardiac Output by the NEXFIN HD Monitor in Peroperative

Study Overview
=================
Brief Summary
-----------------
Continuous perioperative cardiac output (DC) and blood pressure (PA) monitoring contributes to hemodynamic stability and ensures adequate perfusion pressure, resulting in a reduction in morbidity and mortality and length of hospital stay. The monitors usually used in perioperative are either semi-invasive and difficult for calibration (oesophageal Doppler) or invasive (arterial catheter). The Nexfin HD allows these two measurements and it is completely non-invasive, remains to validate its use in peroperative.

Official Title
-----------------
Evaluation of the Measurement of Cardiac Output by the NEXFIN HD Monitor in Peroperative

Conditions
-----------------
Cardiac Output, Peroperative

Intervention / Treatment
-----------------
* Device: Intraoperative heart rate measurement (reference method)
* Device: NEXFIN HD


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients candidate for surgery under general anesthesia requiring oesophageal Doppler or arterial catheter hemodynamic monitoring. Exclusion Criteria: Patients with cardiac and thoracic surgery, patients for whom access to the head is impossible, facial trauma patients, patients with aortic malformation, dilation or coarctation, patients with aortic dissection, patients with vascular surgery with aortic clamping, patients with a tumor, stenosis or varices of the esophagus, patients with severe oesophagitis, patients with thoracic radiotherapy patients under guardianship or curatorship or deprived of liberty.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Measure of the cardiac output obtained by a reference methode<br> | Device: Intraoperative heart rate measurement (reference method)<br>* Measurement of cardiac output by both monitors: NEXFIN HD and oesophageal doppler, blood pressure measurement by the catheter and NEXFIN HD monitor, and cardiac output and blood pressure measurements after treatment administration (vasoconstrictor or filling)<br>|
| Other: Measurement of cardiac output obtained by NEXFIN HD.<br> | Device: NEXFIN HD<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival defines as the time between the date of surgery and death or date of last news |  | 6 months |
Efficacy and Safety of Rimonabant as an Aid to Smoking Cessation With or Without Nicotine Patch

Study Overview
=================
Brief Summary
-----------------
The primary objective is to compare the efficacy of rimonabant 20 mg OD fixed dose plus nicotine patch 21 mg OD with the combination rimonabant 20 mg OD fixed dose plus placebo patch on abstinence from smoking in cigarette smokers motivated to quit. Secondary objectives are to evaluate the clinical and biological safety of rimonabant associated with nicotine replacement therapy during a 9-week treatment period and to evaluate the effect of the combination on weight and craving.

Official Title
-----------------
Single Country, Double-Blind, Randomized, 2-Arm, Parallel-Group Study, Evaluating Efficacy and Safety of Rimonabant 20 mg OD, With/Without Association of Nicotine Patch, as Aid to Smoking Cessation During 9-Week Period

Conditions
-----------------
Smoking Cessation

Intervention / Treatment
-----------------
* Drug: rimonabant (SR141716)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Smokers smoking at least 15 cigarettes/day as a mean within the 2 months preceding the screening visit Motivated to quit with a score greater than or equal to 6 on the ten-point Motivation Scale Exclusion Criteria: non tobacco cigarettes consumption chronic use of marijuana pregnancy breastfeeding any clinically significant disease that might interfere with the efficacy or safety evaluation of the study drug Concomitant use of drugs as an aid to smoking cessation or that might induce weight change

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: rimonabant (SR141716)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prolonged abstinence from smoking during the last 4 weeks of treatment reported by the subject and confirmed by exhaled carbon monoxide (CO) measurements |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy: mean change of the total score of Questionnaire on Smoking Urges (QSU) brief scale, categorical change in body weight in subjects with Body Mass Index lower than 30 kg/m² at baseline who achieve prolonged abstinence |  |  | 
| Safety data |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
abstinence, nicotine patch
Teriparatide for Improved Knee Prosthesis Fixation

Study Overview
=================
Brief Summary
-----------------
The investigators will study how well knee joint prostheses become fixed to the bone when patients get teriparatide, compared to placebo. Measurements will use high resolution 3D radiography (radiostereometry, RSA).

Conditions
-----------------
Osteoarthritis of the Knee

Intervention / Treatment
-----------------
* Drug: teriparatide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Osteoarthritis of the knee planned for prosthesis surgery Exclusion Criteria: Poor health, drugs affecting bone metabolism.

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Teriparatide 20 microgram daily for 2 months<br> | Drug: teriparatide<br> <br> |
| Placebo Comparator: Placebo<br> | Drug: teriparatide<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Migration as measured by RSA maximal total point motion. |  | 2 years |
Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes

Study Overview
=================
Brief Summary
-----------------
Study designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.

Detailed Description
-----------------
Gass in 1987 described three cases of epiretinal membrane (ERM) associated with wet macular degeneration. Since then we have seen that is not rare to find the coexistence of these entities. An ERM may produce intrinsic disorganization of the outer retina leading to persistent increased macular thickness and/or edema. This persistent edema may affect the effectiveness in the treatment of exudative age-related macular degeneration (eAMD). Therefore, this study was designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.

Official Title
-----------------
Visual and Anatomic Outcomes of Intravitreal Anti-VEGF Therapy for Exudative Age-related Macular Degeneration With Concurrent Significant Epiretinal Membrane.

Conditions
-----------------
Epiretinal Membrane, Age Related Macular Degeneration

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Significant epiretinal membrane Anti-VEGF treatment for age-related macular degeneration Exclusion Criteria: Uveitis Macular disorders Diabetic retinopathy Vascular occlusions

Ages Eligible for Study
-----------------
Minimum Age: 58 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best corrected visual acuity | Evaluate the best visual acuity during the follow up. | 12 months | 
| Central macular thickness | Evaluation of the retinal thickness changes with anti-VEGF treatment | 12 months | 
| Fluorescein angiogram | Evaluation of changes in lesion size during follow-up. | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
choroidal neovascularization, epiretinal membrane, anti-VEGF
Food Design for Improved Day-long Glycaemic Regulation

Study Overview
=================
Brief Summary
-----------------
The study focus is on the possible improvement in glucose tolerance at a second standardized meal that can be achieved when preceded by a test meal with a low GI and a high GP.

Detailed Description
-----------------
A study in healthy subjects using spaghetti as the test breakfast and a white wheat bread as the reference. Glycaemia, insulinaemia, NEFA, TG and subjective appetite are studied up to the time of the lunch meal that is served 4h after breakfast. After lunch the blood sampling continues for 2 hours.

Official Title
-----------------
The Effect on Glucose Tolerance at a Second Meal Provided After Breakfast Meal Giving Late Increment in Postprandial Glycaemia

Conditions
-----------------
Poor Glycemic Control

Intervention / Treatment
-----------------
* Other: Reference
* Other: Test product


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI 19-25 Exclusion Criteria: Smoker, Diabetes, Gluten intolerance, vegetarian

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Reference<br>White wheat bread | Other: Reference<br>* the reference product used<br>* Other names: WWB;Other: Test product<br>* The test Product used<br>* Other names: Pasta;|
| Other: Test product<br>Pasta | Other: Reference<br>* the reference product used<br>* Other names: WWB;Other: Test product<br>* The test Product used<br>* Other names: Pasta;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glucose |  | 0-6 h | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Non-esterified fatty acids (NEFA) |  | 0-6 h | 
| Triglycerides (TG) |  | 0-6 h | 
| Appetite rating (Visual Analogue Scale) |  | 0-6 h | 
| Insulin |  | 0-6 h |
Bronchial Colonization With Fungi and Late Respiratory Acquired Pneumonia

Study Overview
=================
Brief Summary
-----------------
Ventilator acquired pneumonia (VAP) are severe nosocomial infections. On the other side, bronchial fungi colonization is commonly observed in ICU; therefore, the investigators propose to study the role of bronchial fungi colonization on the occurrence of VAP taking into account the immune status of the patient and the antibiotic and antifungal treatments he has received.

Official Title
-----------------
Study of the Impact of Bronchial Colonization With Fungi in the Occurrence of Late Ventilator Acquired Pneumonia

Conditions
-----------------
Ventilator Acquired Pneumonia

Intervention / Treatment
-----------------
* Procedure: biological sampling
* Procedure: sampling blood
* Procedure: endotracheal aspiration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient ventilated for at least 5 days Exclusion Criteria: invasive infection Candida sp defined by : candidemia, isolation of Candida from a normally sterile site, candida pneumoniae.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ventilated patient<br>all patients underwent the same diagnostic test . cutaneous, rectal, nose and mouth swabs to identify potential fungi colonization. HLA DR antigen, cytokines (IL 6 and 10), B-glucan. fungi and bacteria endotracheal aspiration | Procedure: biological sampling<br>* cutaneous, rectal, nose and mouth swabs to identify potential fungi colonization<br>Procedure: sampling blood<br>* HLA DR antigen, cytokines (IL 6 and 10), B-glucan<br>Procedure: endotracheal aspiration<br>* fungi and bacteria endotracheal aspiration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Onset of a late ventilator acquired pneumonia (VAP) |  | Participants will be followed for the duration of mechanical ventilation, an expected time frame that can go from 5 days to up to 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Onset of a pseudomonas aeruginosa associated VAP |  | Participants will be followed for the duration of mechanical ventilation, an expected time frame that can go from 5 days to up to 8 weeks | 
| Onset of late ventilator associated pneumonia associated to staphylococcus aureus |  | Participants will be followed for the duration of mechanical ventilation, an expected time frame that can go from 5 days to up to 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
patient ventilated for at least five days
Integrated Care for Cancer Patients; Developing, Implementing and Testing a Programme to Improve Integrated Care

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compose, implement and evaluate a programme to improve the quality of integrated care for patients with cancer. Literature will be searched for components of integrated care programmes. On the basis of evidence based multi-disciplinary guidelines and literature on integrated care programmes, a set of indicators will be composed. This set will be measured in 6 hospitals on patients with non-small-cell-lung cancer. In two hospitals, an integrated care programme will be implemented and effects on processes and outcomes of care will be measured.

Official Title
-----------------
Integrated Care for Cancer Patients

Conditions
-----------------
Neoplasms

Intervention / Treatment
-----------------
* Behavioral: professional audit and feedback
* Behavioral: integrated care programmes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Each new patient that visits the lung specialist in 6 hospitals in the east part of Holland, in the period from September 2004 till March 2005 Exclusion Criteria: Mortality

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Educational/Counseling/Training
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: professional audit and feedback|nan|
|Behavioral: integrated care programmes|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| guideline adherence |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hospitalization |  |  | 
| satisfaction |  |  | 
| quality of life |  |  |